Viiv Healthcare UK (No.5) Limited

Bristol-Myers Squibb Compnay

Amgen Inc.

Viiv Healthcare UK Limited

Zhongyu Wang

B Narasimhulu Naidu

Kevin M Peese

John F Kadow

Manoj Patel

David R Langley

Julio Cesar Medina

Jonathan B Houze

Wang Shen

Zhihua Ma

Zice Fu

Paul John Dransfield

Jiwen Liu

Stanley V D'Andrea

Yingcai Wang

Marc Vimolratana

XianYun Jiao

SuJen Lai

Robert J Cherney

Rajiv Sharma

Michael A Walker

Hilary Plake Beck

Timothy P Connolly

Zhizhen Barbara Zheng

Todd J Kohn

Michael J Schmitt

Jinqian Liu

John V Duncia

Joseph B Santella

Xiaohui Du

Annapurna Pendri

Daniel S Gardner

Liusheng Zhu

Ming Yu

Prasanna Sivaprakasam

Vatee Pattaropong

Sean P Brown

Samuel Gerritz

An-Rong Li

Guo Li

Weixu Zhai

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. 

Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. Formule (I). 

Inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I&#x2032;B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Spirocyclic GPR40 modulators

The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.

Piperidinyl compound as a modulator of chemokine receptor activity

Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: W is CHor O; Q is Formula (II), Formula (III) or Formula (IV); and R, R, R, R, n, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Heterocyclic GPR40 modulators

Growing community of inventors

Tolland, CT, United States of America

Zhongyu Wang